Physician profile
Cheryl Hranicky
NPI 1629086574
$2,755.29
in general payments reported to CMS, 2019-2025
27 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,113 · 2022: $70.96 · 2023: $251 · 2024: $459 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $658.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $448.58 | 2021-2025 | |
| Abbvie INC. | $241.77 | 2021-2024 | |
| Lilly USA, LLC | $163.82 | 2021-2025 | Kisunla, Zepbound, Mounjaro |
| Amgen INC. | $145.53 | 2021-2025 | Repatha, Otezla, Evenity |
| E.R. Squibb & Sons, L.L.C. | $136.56 | 2021-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $105.27 | 2021 | |
| Abbott Laboratories | $95.86 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $89.63 | 2021-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $80.27 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.55 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $64.31 | 2021-2025 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $59.81 | 2021 | |
| Phathom Pharmaceuticals, INC. | $51.33 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $42.21 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.60 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $36.01 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.63 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.11 | 2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $32.95 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $32.27 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.56 | 2023 | Quviviq |
| Upsher-Smith Laboratories LLC | $16.88 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.56 | 2021 | |
| Lundbeck LLC | $13.50 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $13.12 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Hranicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.